
TransMedics Group Q2 Earnings Call Highlights
TransMedics Group (NASDAQ:TMDX) reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure. Total revenue for the quarter ended June 30 rose 21% year over year and 9% sequentially to approximately $190 million. Transplant product revenue increased 16% to $111 million, [...]






